^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR L747-S752 del

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
8ms
NGS Reveals Convergent Acquired Resistance and Newly Emerging Driver Involving MET Alterations in NSCLC: A Case Report (IASLC-WCLC 2023)
Here, we reported a NSCLC patient harboring both METex14skipping and METamp that led to effective second-line treatment with capmatinib after progression on osimertinib. Molecular profiling was performed using a 50-gene hotspot next-generation sequencing (NGS) panel called APEX, which sequences both DNA and RNA molecules. This case represents a unique case of oncogenic addiction to the MET pathway in the metastatic tumor identified with the co-occurrence of METamp and METex14skipping (the latter indicative of the emergence of a new clone). It also underscores the importance of repeat molecular profiling of the metastatic tumor tissue using a broad NGS panel in identifying potential actionable biomarkers to guide treatment selection after disease progression on first-line EGFR-TKI.
Clinical • Preclinical • Next-generation sequencing
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR exon 19 deletion • MET exon 14 mutation • EGFR L747-S752 del
|
Tagrisso (osimertinib) • Tabrecta (capmatinib)
almost2years
Transcriptomic Heterogeneity in Non-Small Cell Lung Cancer Harboring Different EGFR Exon 19 Del/Delins Variants (IASLC-WCLC 2022)
NSCLC with EGFR 19Del/Delins should not be considered as a homogenous disease. NSCLC with uncommon EGFR 19Del/Delins displayed a more active adaptive immunity in tumor microenvironment, which indicated the potential vulnerability of immunotherapy.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • FGFR1 (Fibroblast growth factor receptor 1)
|
EGFR exon 19 deletion • EGFR L747-S752 del • EGFR E746
over3years
Lung adenocarcinoma in a patient with Li-Fraumeni syndrome bearing a novel germ-line mutation, TP53R333Vfs*12. (PubMed, Jpn J Clin Oncol)
She was treated with gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) because of EGFR mutation (L747-S752 del). This TP53 mutation (R333Vfs*12) was first found in lung adenocarcinomas. The therapeutic effect of osimertinib for this triple mutant lung adenocarcinoma is better than the previous report.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
|
TP53 mutation • EGFR mutation • EGFR T790M • EGFR L747-S752 del • TP53 R333Vfs*12
|
Tagrisso (osimertinib) • gefitinib